Skip to main content

Table 1 15-Year survival of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate

From: A 15-Year Follow-up of AJCC Stage III Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus (NDV) Oncolysate and Determination of Alterations in the CD8 T Cell Repertoire

  

Correlation of Survival and No. of Positive Lymph Nodes at Time of Therapeutic Lymph Node Dissection

 

Group

No of Patients

1 Node

2–4 Node

5+ Node

Overall Survival

I

30

10/15 (67%)

8/13 (62%)

0/2 (0)

18/30 (59%)a

II

44

9/20 (45%)

8/14 (57%)

6/10 (60%)

23/44 (53%)b

  1. aIncludes one patient currently with recurrent metastatic melanoma, and one patient currently with prostate cancer.
  2. bIncludes one patient currently with breast cancer.
Back to article page

Molecular Medicine

ISSN: 1528-3658